Risk of Dyslipidemia and Major Adverse Cardiac Events with Tofacitinib Versus Adalimumab in Rheumatoid Arthritis: a Real-World Cohort Study from 7580 Patients
Frontiers in Pharmacology（2024）
关键词
tofacitinib,adalimumab,lipidemias,risk factors,TriNetX
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要